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ARTICLE
A Flexible Bayesian Framework for Modeling Haplotype
Association with Disease, Allowing for Dominance Effects
of the Underlying Causative Variants
Andrew P. Morris
Multilocus analysis of single-nucleotide–polymorphism (SNP) haplotypes may provide evidence of association with dis-
ease, even when the individual loci themselves do not. Haplotype-based methods are expected to outperform single-SNP
analyses because (i) common genetic variation can be structured into haplotypes within blocks of strong linkage dis-
equilibrium and (ii) the functional properties of a protein are determined by the linear sequence of amino acids corre-
sponding to DNA variation on a haplotype. Here, I propose a ﬂexible Bayesian framework for modeling haplotype
association with disease in population-based studies of candidate genes or small candidate regions. I employ a Bayesian
partition model to describe the correlation between marker-SNP haplotypes and causal variants at the underlying func-
tional polymorphism(s). Under this model, haplotypes are clustered according to their similarity, in terms of marker-
SNP allele matches, which is used as a proxy for recent shared ancestry. Haplotypes within a cluster are then assigned
the same probability of carrying a causal variant at the functional polymorphism(s). In this way, I can account for the
dominance effect of causal variants, here corresponding to any deviation from a multiplicative contribution to disease
risk. The results of a detailed simulation study demonstrate that there is minimal cost associated with modeling these
dominance effects, with substantial gains in power over haplotype-based methods that do not incorporate clustering
and that assume a multiplicative model of disease risks.
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It is widely accepted that population-baseddisease-marker
association studies of samples of unrelated affected cases
and unaffected controls have the potential to map genes
contributing to complex traits, provided that the causative
variants are not extremely rare.1,2 The success of this ap-
proach relies on genotyping genetic markers—typically
SNPs that are in strong linkage disequilibrium (LD) with
the functional polymorphism(s)—generated as a result of
the shared ancestry of sampled individuals in the ﬂanking
region. Initial association studies focused on genotyping
high-density SNPs in candidate genes with a functional
basis for disease and/or located in regions highlighted by
the results of previous linkage-based analyses. However,
with improvements in the efﬁciency of high-throughput
SNP genotyping technology, genomewide scans of hun-
dreds of thousands of markers are now under way with
the large sample sizes required to detect the modest ge-
netic effects we expect for complex traits.3
One of the most attractive features of SNPs for complex
disease-gene mapping is their abundance throughout the
genome. However, single-locus analyses—testing for dis-
ease association with each SNP, in turn—do not take into
account the background patterns of LD between loci and,
hence, may be inefﬁcient even before the issue ofmultiple
testing with many markers is addressed. Data from the
International Haplotype Map (HapMap) project suggest
that much of the human genome can be arranged in
blocks of common SNPs in strong LD with one another.4,5
Haplotype diversity within blocks is very much driven by
mutation, rather than by ancestral recombination events.
Thus, much of common genetic variation can be struc-
tured into haplotypes within blocks that are rarely dis-
turbed by meiosis. Furthermore, Clark6 emphasizes that
the functional properties of a protein are determined by
the linear sequence of amino acids corresponding to DNA
variation on a haplotype. For example, there is evidence
that a combination of causal variants in cis in the HPC2/
ELAC2 gene increases the risk of prostate cancer.7 This
suggests that appropriate multilocus analyses of SNP hap-
lotypes within blocks of strong LD may provide evidence
of association for modest genetic effects, even when the
individual polymorphisms themselves do not.
The most convenient framework for the development
of statistical methodology for multilocus analyses of pop-
ulation-based association studies is the logistic-regres-
sion model. It is common to assume a multiplicative
model of disease risks, so that paternally and maternally
derived alleles contribute independent effects. Under this
assumption, the logistic-regression model can be parame-
terized in terms of the risk (or, more precisely, the odds)
of disease for each marker-SNP haplotype. Within this
framework, it is straightforward to accommodate covari-
ates that may include environmental and other nonge-
netic risk factors, polygenic effects, and genotypes at an-
cestrally informative markers, to allow for underlying
population stratiﬁcation. To allow for unknown phase, we
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consider all possible pairs of haplotypes consistent with
the observed genotype data for each individual.8–11 Each
consistent haplotype conﬁguration is weighted in the lo-
gistic-regression likelihood by the corresponding phase-
assignment probability, easily estimated within blocks of
strong LD by statistical algorithms, such as PHASE,12,13 that
also take into account additional uncertainty due to miss-
ing genotype data.
A major limitation of haplotype-based analyses is lack
of parsimony, since we require an odds parameter in the
logistic-regression model for each distinct marker-SNP
haplotype consistent with the observed genotype data.
However, we can take advantage of the expectation that
chromosomes carrying the same causal variant tend to
share more-recent common ancestry at the underlying
functional polymorphism(s) than do a random pair from
the population and, thus, are more likely to carry similar
haplotypes in the ﬂanking genomic region. Thus, by clus-
tering marker-SNP haplotypes according to their similar-
ity, we can assign the same genetic effect(s) to haplotypes
within the same clade, reducing the number of parameters
in the logistic-regression model, without substantial loss
of information.11,14–21 Morris11 clusters marker-SNP hap-
lotypes according to a Bayesian partition model.22,23 The
model is speciﬁed by selecting cluster “centers” from the
set of distinct haplotypes consistent with the observed
genotype data, identiﬁed via implementation of the ex-
pectation-maximization (EM) algorithm.24 The remaining
haplotypes are then assigned to the nearest cluster center,
where similarity is deﬁned in terms of marker-allele
matches, appropriate for haplotype diversity driven by
mutation, such as that expected within blocks of SNPs in
strong LD with each other.
In this article, I generalize the approach developed by
Morris,11 to allow for more-ﬂexible modeling of marker-
SNP haplotype association with disease—in particular, to
account for dominance effects, here corresponding to
any deviation from multiplicative disease risks. This is
achieved by introducing a latent variable to describe the
presence or absence of causal variants at the functional
polymorphism(s) on eachmarker-SNP haplotype, in away
similar to that of Clayton et al.25 I assume that each causal
variant has the same genetic effects on disease. Thus, the
logistic-regression model can be parameterized in terms
of (i) the additive effect (or multiplicative risk) of causal
variants and (ii) the dominance effect of causal variants
over other alleles at the functional polymorphism(s). The
Bayesian partition model is then used to describe the cor-
relation between marker-SNP haplotypes and alleles at the
functional polymorphism(s). Under this model, each hap-
lotype allocated to the same cluster is assigned the same
probability of carrying a causal variant. I develop a re-
versible-jump Markov chain–Monte Carlo (MCMC) al-
gorithm, GENEBPMv2, to sample over the space of hap-
lotype clusters and the corresponding probabilities that
they carry a causal variant at the functional polymor-
phism(s), in addition to additive and dominance effects
of the causal variants and covariate-regressioncoefﬁcients.
The GENEBPMv2 algorithm can be used to assess the
evidence in favor of disease association with polymor-
phisms in a candidate gene or a small candidate region.
However, as the length of the candidate region increases,
recombination will play an increasingly important role
in driving haplotype diversity, and there will be greater
uncertainty and less accuracy in phase assignment from
unphased genotype data. I illustrate the method by ap-
plication to high-density unphased SNP-genotype data
across an 890-kb candidate region ﬂanking the CYP2D6
gene, for association with a recessive poor-drug-metabol-
izer (PDM) phenotype.26 The results ofmy analysis provide
overwhelming evidence of association of the PDM phe-
notype with polymorphisms in the candidate region and
correctly highlight the recessive effect of the underlying
causal variants. Further, I identify two clusters of haplo-
types, both with high probability of carrying different
causal variants in CYP2D6, relative to all other haplotypes.
Consequently, I am able to distinguish individuals with
PDM carrying two copies of the most common causal var-
iant from those carrying rarer, high-risk mutations at the
functional polymorphisms in CYP2D6.
Dominance is often overlooked in haplotype-based as-
sociation studies because the gain in power over a model
of multiplicative disease risks is generally not appreciable,
unless there is a strong recessive effect of the causative
variant or there is overdominance, and because there is a
fear that a less parsimonious model will lose power as a
result of the multiple-testing burden. However, I dem-
onstrate, by simulation, that, within the Bayesian frame-
work developed here, there is minimal loss in power from
allowance for deviations from a multiplicative model of
disease risks with the GENEBPMv2 algorithm. Encourag-
ingly, my results suggest substantial gains in power over
existing haplotype-based tests of association that do not
allow for dominance and clustering. This clearly dem-
onstrates that, with an appropriate analysis such as that
implemented here in the GENEBPMv2 algorithm, domi-
nance effects can and should be included in haplotype-
based association studies to increase power without pen-
alty for reduced parsimony.
Model and Methods
Consider a case-control sample of unrelated individuals, typed at
N marker SNPs in a candidate gene or small candidate region,
yielding unphased genotypes G. Alleles at each SNP are coded as
“1” for the major allele (i.e., the most frequent in the population)
and as “2” for the minor allele. The disease status of individual
i is denoted if affected and if unaffected. I allow fory p 1 y p 0i i
additional covariates, x, each scaled to have zero mean and unit
variance. The set of J distinct marker-SNP haplotypes consistent
with the observed unphased genotypes is denoted H p
, where denotes the jth most frequent haplotype.{H ,H ,… ,H } H1 2 J j
Relative haplotype frequencies,h, are estimated bymeans ofmax-
imum likelihood via implementation of the EM algorithm,where
www.ajhg.org The American Journal of Human Genetics Volume 79 October 2006 681
Figure 1. DAG representing the model underlying the likelihood,
, given by equation (3). The gray nodes representf (yFG,x,h,v)
observed data and estimated relative haplotype frequencies, ob-
tained via implementation of the EM algorithm. The likelihood
depends on a number of model parameters, —including the base-v
line risk of disease (m), covariate-regression coefﬁcients ( ), andg
genetic effects ( )—of causative variants at the functional poly-b
morphism(s). To evaluate the likelihood, I allow for the correlation
between marker-SNP haplotypes ( ) and genotypes (Z) at the func-H
tional polymorphism(s), by means of a Bayesian partition model.
The model is parameterized in terms of the number of clusters of
haplotypes (K), the cluster centers ( ), and the probability (f)C
that haplotypes within each cluster carry a causative variant at
the functional polymorphism(s). The parameters, , depend on thev
underlying model of association ( ) of disease with marker SNPs.M
Under the null model, , the genetic effects are zero, and thereM0
is a single cluster of haplotypes. Under the alternative model of
association, , I allow for dominance effects of the causativeM1
variants at the functional polymorphism(s), and there are at least
two clusters in the partition of haplotypes.
denotes the frequency of . I denote by the seth H Dp {y,G,x,h}j j
of observed data and estimated haplotype frequencies.
I assume that alleles at the functional polymorphism(s) in the
candidate gene can be classiﬁed as high-risk “causative” variants
and as low-risk “protective” variants. Each causative variant is
assumed to confer the same risk of disease, and likewise for pro-
tective variants. I can then model the log-odds of disease within
a logistic-regression framework, parameterized in terms of addi-
tive and dominance effects of the causative variant, denoted bA
and bD, respectively. Under the null model, , of no associationM0
of disease with polymorphisms in the candidate region, b pA
, whereas the alternative model, , corresponds tob p 0 M b 1D 1 A
and bD unconstrained. Within the Bayesian paradigm, it is com-0
mon to evaluate the evidence against the null model by means
of the Bayes factor,
( )f yFG,x,h,M1
L p , (1)( )f yFG,x,h,M0
where denotes the marginal likelihood of observedf (yFG,x,h,M)
phenotype data under model .M
The marginal likelihood of model can be calculated by in-M
tegration over model parameters , summarized by the directedv
acyclic graph (DAG) in ﬁgure 1. Model parameters include the
genetic effects bA and bD but also baseline log-odds of disease, m,
and covariate-regression coefﬁcients, . However, since I do notg
observe genotypes at the functional polymorphism(s) directly, v
must also include parameters to describe the correlation between
causal variants andmarker-SNP haplotypes in the candidate gene,
here taken to be speciﬁed by a Bayesian partition model. Then,
( ) ( ) ( )f yFG,x,h,M ∝ f yFG,x,h,v f vFM v , (2)
v
where denotes the likelihood of observedphenotypef (yFG,x,h,v)
data, given parameters , and is their joint prior densityv f (vFM)
under model .M
Bayesian Partition Model
The Bayesian partition model is deﬁned by specifying K cluster
centers, ordered and without replacement from the set of hap-
lotypes, , denoted by . Haplotype is thenH C p {C ,C ,… ,C } H1 2 K j
assigned to the cluster with the maximum similarity metric, de-
ﬁned as
N1
S p sjk jk(n)Nnp1
for the kth cluster center, . The nth SNP similarity metric,Ck
, is given bysjk(n)
q if H p C p 1n j(n) k(n)
( )s p 1 q if H p C p 2 ,jk(n) n j(n) k(n){0 if H ( Cj(n) k(n)
where and denote the allele present at SNP n on hap-H Cj(n) k(n)
lotype and cluster center , respectively, and denotes theH C qj k n
relative sample frequency of the minor allele in controls. If hap-
lotype is equidistant from more than one cluster center, it isHj
assigned to the center with minimum k. According to the Bayes-
ian partition model, each haplotype assigned to the same clade
is then assumed to have the same probability of carrying a causal
variant at the functional polymorphism(s), denoted for the kthfk
cluster.
The similaritymetric, , treats haplotypes that share rare allelesSjk
as less diverse than those that share common alleles, because they
are expected to share more-recent common ancestry. Thus, I
quantify allele sharing by the complimentary-allele frequency, in
the same way as did Durrant et al.20—that is, by for minor-1 qn
allele sharing at SNP n and by for major-allele sharing. A num-qn
ber of alternative metrics have been proposed—for example,
those that weight SNP-allele matches according to their distance
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from a putative disease locus in the context of ﬁne mapping18 or
that allow for mismatch of alleles due to ancestral mutation or
gene-conversion events.21
Likelihood Calculation
To calculate the likelihood term, , in equation (2), If (yFG,x,h,v)
must consider all possible pairs of marker-SNP haplotypes con-
sistent with the observed unphased genotype data. Then, the
likelihood can be expressed as a summation over H, weighted by
the corresponding phase-assignment probabilities, given by
( ) ( ) ( )f yFG,x,h,v∝ f y FH ,H ,x ,v f H ,H FG ,h . (3) i j j i j j i1 2 1 2
i j j1 2
Assuming Hardy-Weinberg equilibrium,
h hj j1 2( )f H ,H FG ,h pj j i1 2 ( )f G Fhi
and , where is an in-f (G Fh) p   f (G FH ,H )h h f (G FH ,H )i i j j j j i j jj j 1 2 1 2 1 21 2
dicator variable of the consistency of the genotype with theGi
pair of haplotypes and .H Hj j1 2
I must then consider the three possible genotype categories at
the functional polymorphism(s), denoted by , cor-Zp {00,01,11}
responding, respectively, to two protective variants (not neces-
sarily copies of the same allele), to one protective variant and
one causative variant, and to two causative variants (not neces-
sarily copies of the same allele). Thus, denoting the genotype of
the ith individual at the functional polymorphism(s) by , itZi
follows that
( ) ( ) ( )f y FH ,H ,x ,v p f y FZ ,x ,b ,b ,m,g f Z FH ,H ,f ,i j j i i i i A D i j j1 2 1 2
ZZi
where
( )f Z FH ,H ,fi j j1 2
1f 1f if Z p 00( ) ( )T T iC(j ) C(j )1 2
p f 1f  1f f if Z p 01( ) ( )T T T T iC(j ) C(j ) C(j ) C(j )1 2 1 2{
f f if Z p 11T T iC(j ) C(j )1 2
and denotes the cluster assignment of haplotype in par-T HC(j) j
tition . Finally, within a logistic-regression framework,C
yi( )exp hi( )f y FZ ,x ,b ,b ,m,g p ,i i i A D ( )1exp hi
where the linear component, , is given byhi
m g x  b if Z p 00 l il A i
l
h p m g x  b if Z p 01 .i l il D i
l{
m g x  b if Z p 11 l il A i
l
Prior-Density Function
The Bayes factor (L) in favor of disease association with poly-
morphisms in the candidate gene depends crucially on the prior-
density function of parameters, , under each model .f (vFM) M
Logistic-regression model parameters are assumed a priori to be
independent of the partition of haplotypes. The baseline log-odds
of disease is assumed to have a uniform prior distribution,
whereas covariate-regression coefﬁcients are assumed to have in-
dependent standard normal prior distributions, irrespective of the
model of association. Under the null model, , the genetic ef-M0
fects and the haplotype clustering is irrelevant tob p b p 0A D
disease risk, so that
1( )f vFM ∝exp  g .0 l[ ]( )2 l
Conversely, under the alternative model, , the genetic effectsM1
are assumed a priori to have standard normal distributions, sub-
ject to the constraint . In deﬁning the Bayesian partitionb 1 0A
model, each haplotype in has equal prior probability of selec-H
tion as one of the K cluster centers, where each cluster has in-
dependent uniform prior probability of carrying a causal variant
at the functional polymorphism(s). Furthermore, the uncondi-
tional prior density of the number of clusters, , has a geo-K 1 1
metric distribution, such that . Thus,f (K 1) /f (K) p 0.5
( )nK ! 1( )f vFM ∝ exp  b  b  g .1 A D l[ ]K ( )2 2 l
I investigate the properties of the Bayes factor, L, for these prior-
density functions by simulation, explained below.
MCMC Algorithm
I have developed a Metropolis-Hastings MCMC algorithm27,28 to
approximate the posterior density of parameters under model
, given byM
( ) ( ) ( )f vFD,M ∝f yFG,x,h,v f vFM , (4)
in the integrand of equation (2). The dimensionality of dependsv
on the number of clusters, K, of haplotypes. This can be addressed
by incorporating a birth-death process for the number of clusters
via implementation of a reversible-jump step in the MCMC al-
gorithm.29 At each stage of the algorithm, a new candidate set of
parameter values, , is proposed by making a small change to′v
the current set, , as detailed in appendix B. The proposed set ofv
parameter values is then accepted in place of , with probabilityv
proportional to ; otherwise, the current set is′f (v FD,M) /f (vFD,M)
retained.
The MCMC algorithm is run for an initial burn-in period to
allow convergence from a randomly selected set of starting values
of , assessed using standard diagnostics.30 After convergence,v
each set of parameter values accepted, or retained, by the algo-
rithm represents a random draw from the posterior density
. Autocorrelation between consecutive draws is reducedf (vFD,M)
by recording the sampled set of parameter values only at every
tth iteration of the algorithm, for some suitably large t.
To approximate the Bayes factor in equation (1), I perform two
independent runs of the MCMC algorithm—one under the null
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model, , and one under the alternative model, . Over R re-M M0 1
corded MCMC outputs for each independent run,
ˆ ( )f yFG,x,h,M1
L ≈ ,
ˆ ( )f yFG,x,h,M0
where
11 (r) 1
ˆ ( ) ( )f yFG,x,h,Mp f yFG,x,h,v , M[ ]R r
and denotes the likelihood in equation (3), re-(r)f (yFG,x,h,v )M
corded in the rth output under model .M
Interpretation
The Bayes factor, L, reﬂects the strength of evidence in favor of
disease association with polymorphisms in the candidate gene.
By convention, corresponds to positive evidence oflog L 1 0.510
association, whereas and correspond tolog L 1 1 log L 1 210 10
strong and decisive evidence, respectively.31 The posterior prob-
ability of association can then be approximated by
( )Lf M1
,( ) ( )Lf M f M1 0
where is the prior probability against the nullf (M ) p 1 f (M )1 0
model, reﬂecting beliefs about association between disease and
polymorphisms in the candidate gene before the data is looked
at. This probability might take into account the functional rel-
evance of the gene or the results of previous linkage and asso-
ciation studies of the same disease. The issue of multiple testing
with many candidate genes or regions can also be addressed by
increasing the prior probability in favor of the null model for
each.32
Software Availability
The GENEBPMv2 software has been developed to (i) obtain max-
imum-likelihood estimates of the relative frequencies of haplo-
types consistent with a sample of observed SNP genotypes, via
application of the EM algorithm; (ii) implement the MCMC al-
gorithm to sample over the space of covariate-regression coefﬁ-
cients under the null model of no association; (iii) implement
the reversible-jump MCMC algorithm to sample over the space
of haplotype clusters and the corresponding probabilities that
they carry the causal variant at the functional polymorphism(s),
in addition to the additive and dominance effects of the causal
variant and covariate-regression coefﬁcients under the alternative
model of association; and (iv) estimate L and summarize the out-
put of the MCMC algorithm. The GENEBPMv2 software is avail-
able, as a suite of Linux executables, on request from the author.
Results
In this section, I demonstrate the utility of the proposed
method by applying the GENEBPMv2 algorithm to the
detection of association of the PDM phenotype with poly-
morphisms in the CYP2D6 gene. I also present the results
of a simulation study to investigate the performance of
the GENEBPMv2 algorithm to detect disease association
with polymorphisms in candidate regions of up to 100 kb
in length.
Example Application: CYP2D6
The gene CYP2D6 on human chromosome 22q13 has an
established role in drug response and is known to be in-
volved in the metabolism of ∼20% of commonly pre-
scribed compounds.33 Four functional polymorphisms
have been identiﬁed in the gene; the most common mu-
tation, G1846A, occurs with relative frequency of 20.7%
in the general population.34 The PDM phenotype acts in
a recessive fashion and is manifested in individuals ho-
mozygous or compound heterozygous for causal variants
at these functional polymorphisms.
Hosking et al.26 genotyped 1,108 individuals at 32 SNP
markers across an 890-kb region ﬂanking CYP2D6, to eval-
uate the efﬁcacy of mappingmethods to identify the gene.
By the typing of the sample at the four known functional
polymorphisms, 41 individuals were predicted to have the
PDM phenotype. Single-locus analysis of the markers
identiﬁed 10 SNPs displaying strong association with the
PDM phenotype and residing in a block of strong LD that
includes CYP2D6. Here, I apply the GENEBPMv2 software
to the 32 marker SNPs (excluding the functional poly-
morphisms) to demonstrate (i) evidence of the recessive
effect of causal variants in CYP2D6, by allowing for de-
viations from a multiplicative model of PDM phenotype
risks, and (ii) clustering of haplotypes carrying the same
causal variant in CYP2D6.
Implementation of the EM algorithm identiﬁed 906
haplotypes consistent with the observed marker-SNP ge-
notype data. There were 17 common haplotypes with es-
timated relative frequency of at least 1%. I performed two
independent runs of the MCMC algorithm: once under
the null model ( ) and once under the alter-b p b p 0A D
native model ( and unconstrained). Each run ofb 1 0 bA D
the MCMC algorithm consisted of an initial 100,000 it-
eration burn-in period, to allow convergence from a ran-
dom starting parameter set. In the subsequent 1,000,000-
iteration sampling period, output of the algorithm was
recorded every 1,000th iteration.
Figure 2 presents a summary of output from the sam-
pling period of the MCMC algorithm (1,000 recorded out-
puts) under the alternative model of association. Figure
2A and 2B presents the prior and posterior distributions
of the additive and dominance effects of causative variants
at functional polymorphisms in CYP2D6, with ﬁgure 2C
demonstrating the posterior correlation between them. Fi-
nally, ﬁgure 2D presents the posterior distribution of the
number of clusters, here ranging from 3 to 9, with a mode
of 4. The L is 48.436, which provides overwhelminglog10
evidence in favor of association of the PDM phenotype
with polymorphisms in the candidate region. The poste-
rior mean (SD) additive and dominance effects of causal
variants in CYP2D6 are estimated as 4.17 (0.52) and
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Figure 2. Summary of the output of a single run of the MCMC algorithm under the general alternative model of association with the
PDM phenotype for 32 marker SNPs across an 890-kb region ﬂanking the CYP2D6 gene. A, Prior and posterior distribution of additive
effects of causal variants. B, Prior and posterior distribution of dominance effects of causal variants. C, Correlation between the posterior
distribution of additive and dominance effects of the causal variants. D, Posterior distribution of the number of clusters of haplotypes.
Figure 3. Dendogram of the 17 common haplotypes from a sin-
gle run of the MCMC algorithm under the general alternative model
of association with the PDM phenotype for 32 marker SNPs across
an 890-kb region ﬂanking the CYP2D6 gene. Haplotypes are coded
according to their relative frequency, where 1 denotes the most
common. Haplotypes within the four clusters, labeled “A–D,” are
similar in terms of allele matching and their risk of carrying causal
variants for the PDM phenotype.
2.26 (0.67), respectively. The dominance effect is neg-
ative, which correctly highlights the recessive nature of
deviations from the multiplicative model of disease risks.
Figure 3 presents a summary of the posterior partition
of common marker-SNP haplotypes across the 890-kb re-
gion ﬂanking the CYP2D6 gene under the alternative
model, identifying four clear clusters, labeled “A–D.” The
dendogram was constructed using standard average-link-
age hierarchical-clustering techniques35 based on a pos-
terior measure of pairwise similarity, given by the pro-
portion of MCMC outputs in which each pair of haplo-
types appears in the same cluster of the Bayesian partition
model. To interpret the clustering, I estimate the posterior
probability, , that haplotype carries a causal variantw Hj j
at the functional polymorphisms in CYP2D6 (table 1).
Over R outputs of the MCMC algorithm,
1 (r)w p f ,j T (j)CR r
where denotes the probability that haplotype car-(r)f HT (j) jC
ries a causal variant at the functional polymorphisms re-
corded in the rth output.Marker-SNP haplotypes in cluster
A have a 98% probability of carrying a causal variant,
whereas those in cluster B have a 15%–16% probability,
both considerably higher than the baseline risk of 1%–2%
in clusters C and D. Note that, for a case-control study,
does not represent the population risk of carrying awj
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Table 1. Approximate Posterior Probability That CarriesHj
a Causal Variant at the Functional Polymorphisms in
CYP2D6
Marker-SNP Haplotype Hj Cluster
a j
hj
(%) ˆwj
11111111121121111121111121222111 A 3 3.42 .979
11111111121121111121111121221111 A 5 2.42 .979
11111111121121111121111121111111 A 6 2.35 .979
22122111111212211112111111111111 B 11 1.66 .143
22122111111212211112111111111221 B 17 1.10 .143
11111111111111122211111112221111 C 2 4.66 .009
22122111212121121211111111112111 C 7 2.34 .015
11111111121111122211111112221111 C 9 1.71 .009
22122111212121121211111111111121 C 10 1.71 .012
11111222112111122211111112221111 C 16 1.20 .009
11111111111212211112111111221111 D 1 6.90 .017
11111111111212211112111111111121 D 4 3.02 .019
11111111111212211112111111112111 D 8 1.90 .020
11111111111212211112111111221112 D 12 1.65 .018
11111111111212211112111111111111 D 13 1.52 .017
11111111111212211112111111111221 D 14 1.40 .020
11111111111212211122111111221111 D 15 1.33 .022
a Clusters correspond to four clades identiﬁed in the dendogram of
haplotypes (ﬁg. 3).
causal variant on haplotype , since the sample is en-Hj
riched for affected individuals and, thus, for high-risk
alleles.
As a ﬁnal stage in the analysis, I investigated the relat-
edness of the 41 individuals with the PDM phenotype,
illustrated by the dendogram presented in ﬁgure 4, con-
structed using hierarchical-clustering techniques based on
the output of the MCMC algorithm for the alternative
model. Similarity between a pair of individuals is given
by the posterior mean number of haplotypes they share
from the same cluster of the Bayesian partitionmodel over
all MCMC outputs. For the rth output, the mean sharing
is calculated over all possible haplotype conﬁgurations
consistent with the observed genotype data of the pair of
individuals, weighted by the corresponding phase-assign-
ment probabilities. For each combination of phase assign-
ments, sharing is scored as “2” if the individuals share
both pairs of haplotypes from the same cluster(s), as “1”
if they share one pair of haplotypes from the same cluster,
and as “0” otherwise.
Figure 4 indicates the genotype of each individual at
functional polymorphism(s) in CYP2D6: “1” corresponds
to the common G1846A mutation, whereas “2” and “3”
correspond to rarer mutations delA2548 and delT1707,
respectively. The dendogram distinguishes, with remark-
able accuracy, individuals with different CYP2D6 geno-
types. The 32 individuals carrying the 1/1 genotype form
a tight cluster, with posterior mean sharing of haplotypes
from the same cluster close to 2, as would be expected.
All 32 of these individuals carry two haplotypes from clus-
ter A, which suggests that this clade is highly associated
with the G1846A mutation in CYP2D6. The seven indi-
viduals carrying the 1/2 genotype also form a tight cluster.
In addition to carrying one haplotype from cluster A, all
seven of these individuals also carry one haplotype from
cluster B, which suggests that this rarer clade is highly
associated with the delA2548mutation inCYP2D6.Morris
et al.36 analyzed the same data in an attempt to ﬁne map
functional polymorphisms in the CYP2D6 gene, using the
COLDMAP software. Their analysis was also able to dis-
tinguish cases carrying zero, one, or two copies of themost
common mutation in the gene, although the clustering
was not quite so clear cut.
Simulation Study
For simulation purposes, I consider a range of complex
disease models for different causative variant frequencies
at a single functional polymorphism. For each simulation
model, I generate 1,000 replicates of unphased marker-
SNP genotype data for unrelated cases and controls. Each
replicate is obtained as follows:
1. Generate an ancestral recombination graph37 for a pop-
ulation of 20,000 SNP haplotypes from a realization of
the coalescent process with recombination, simulated
using the MS software.38 I assume scaled mutation and
recombination rates of 4 per 10 kb of the region.39 For
an effective population size of 10,000 individuals, this
corresponds to a mutation rate of per site, per810
chromosome, and per generation, and a uniform re-
combination rate of 1 cM per Mb.
2. Select the functional polymorphism at random from
all SNPs, so that the causative variant will occur at a
rate close to the predeﬁned frequency.
3. Select markers at random from the remaining SNPs,
with probability , where p is the minor-allele4p (1 p)
frequency (MAF). This distribution reﬂects the bias in
MAF towards common SNPs in public databases, such
as the International HapMap project.4,5
4. Generate a diploid individual by sampling a pair of
haplotypes, at random and with replacement, from the
population of 20,000 chromosomes. Generate the dis-
ease phenotype of the individual according to their
genotype at the functional polymorphism and the pre-
deﬁned simulation diseasemodel. Repeat this step until
the required number of cases and controls have been
simulated.
5. Retain the unphased genotype of each individual only
at the marker SNPs.
For each replicate of data, I obtainmaximum-likelihood
estimates of marker-SNP haplotype frequencies via imple-
mentation of the EM algorithm. I then perform two in-
dependent runs of the MCMC algorithm: once under the
null model of no association ( ) and once underb p b p 0A D
a general alternativemodel allowing for nonmultiplicative
disease risks ( and unconstrained). Each run ofb 1 0 bA D
the MCMC algorithm consists of an initial 100,000 iter-
ation burn-in period, with output recorded every 1,000th
iteration in the subsequent 1,000,000-iteration sampling
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Figure 4. Denodogram of the 41 cases from a single run of the MCMC algorithm under the general alternative model of association
with the PDM phenotype for 32 marker SNPs across an 890-kb region ﬂanking the CYP2D6 gene. The dendogram is constructed to
illustrate the relatedness of individuals in terms of the posterior mean number of haplotypes they share from the same cluster (ﬁg. 3).
Individuals with PDM are coded according to their genotype at functional polymorphisms in the CYP2D6 gene, where 1 is the G1846A
mutation, 2 is the delA2548 mutation, and 3 is the delT1707 mutation.
period. For each replicate of data, output from each run
of the MCMC algorithm is used to approximate L.
Table 2 presents summary statistics to assess the prop-
erties of the GENEBPMv2 algorithm under the null sim-
ulation model, in which all individuals have the same risk
of disease, regardless of their genotype at the functional
polymorphism. Results are presented for a range of dif-
ferent candidate regions and sample sizes. As expected,
the LD between marker SNPs decreases as the length of
the candidate region—and, hence, the distance between
them—increases. As a consequence, there is greater hap-
lotype diversity in larger candidate regions. For larger sam-
ple sizes, the mean number of haplotypes increases, since
there is greater opportunity to observe rare haplotypes.
The mean number of common haplotypes, however, is
unaffected by sample size. The mean number of clusters
in the partition of haplotypes increases with the length
of the candidate region but decreases with sample size.
This reﬂects the increased haplotype diversity in large can-
didate regions but the reduced variability in cluster mem-
bership for larger sample sizes. The mean L is closelog10
to zero, irrespective of the length of the candidate region
and sample size. The proportions of replicates with posi-
tive and strong evidence of association are ∼7%–8% and
∼1%–2%, respectively.
I next consider a simulation model of disease-marker
association, parameterized in terms of (i) the population
frequency of the causal variant and (ii) the genotype rel-
ative risks (GRRs) of individuals homozygous and hetero-
zygous for the causal variant, with the homozygous pro-
tective variant genotype as baseline. Figure 5 presents the
mean number of clusters in the partition of haplotypes,
as a function of the disease model for candidate regions
of 30 and 100 kb in length, typed at 5 and 20 SNPs, re-
spectively, each for samples of 1,000 cases and 1,000 con-
trols. As expected, the mean number of clusters increases
with the strength of association between disease and the
functional polymorphism. The number of clusters is
greatest in candidate regions 100 kb in length, presumably
because of the increased haplotype diversity (table 2).Nev-
ertheless, this still reﬂects improved parsimony in com-
parison with the number of distinct haplotypes consistent
with the observed genotype data.
Figure 6 presents the mean L in favor of diseaselog10
association as a function of the disease model for candi-
date regions of 30 and 100 kb, typed at 5 and 20 marker
SNPs, respectively, each for samples of 1,000 cases and
1,000 controls. The results are entirely as expected, where
the magnitude of L increases with causal-variant fre-
quency and with the strength of association between dis-
ease and the functional polymorphism. Furthermore, for
a ﬁxed causal-variant frequency, the mean L is gen-log10
erally higher in large candidate regions with greater hap-
lotype diversity. This presumably reﬂects increased pre-
cision in clustering of haplotypes carrying the causal
variant, despite the effects of recombination on the sim-
ilarity metric and phase-reconstruction process.
Loss of information by ignoring dominance.—For each rep-
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Figure 5. Mean number of clusters in the partition of haplotypes
as a function of the disease model for samples of 1,000 cases and
1,000 controls for causative-allele frequencies of 0.05, 0.2, and
0.5 in a candidate region of 30 kb, typed at 5 SNPs (A), and for
a causative-allele frequency of 0.2 in candidate regions of 30 and
100 kb, typed at 5 and 20 SNPs, respectively (B).
Table 2. Summary Statistics over 1,000 Replicates of Data Generated According to M0
No. of Markers, Candidate-Region
Size, and No. of Cases/Controls
Mean
MAF
Mean
a2r
Mean No. of
Haplotypes
(Common)b
Mean
No. of
Clusters
log L10
Mean 1.5c 11c
5 SNPs in 30 kb:
200/200 .239 .189 9.31 (4.89) 2.85 .033 .073 .020
500/500 .237 .185 9.88 (4.86) 2.78 .061 .073 .010
1,000/1,000 .237 .181 10.2 (4.86) 2.72 .064 .072 .021
10 SNPs in 50 kb:
200/200 .239 .145 25.0 (6.36) 2.91 .015 .070 .018
500/500 .244 .150 27.7 (6.45) 2.84 .043 .076 .015
1,000/1,000 .238 .142 29.3 (6.43) 2.75 .060 .083 .023
20 SNPs in 100 kb:
200/200 .241 .102 72.4 (4.58) 2.93 .001 .076 .016
500/500 .242 .102 85.7 (4.56) 2.85 .039 .068 .011
1,000/1,000 .240 .101 95.9 (4.48) 2.77 .016 .080 .011
a Between pairs of marker SNPs.
b Mean number of haplotypes consistent with observed genotype data; in parentheses, mean number
of common haplotypes (15% relative sample frequency).
c Proportion of replicates with positive (10.5) and strong (11) evidence of association.
licate of data, I perform a third independent run of the
MCMC algorithm, this time under the alternative model
of association assuming multiplicative disease risks (b 1A
and ). Figure 6 presents the increase in the mean0 b p 0D
L, by allowing for deviations from thismultiplicativelog10
model, as a function of the disease model for candidate
regions of 30 and 100 kb, typed at 5 and 20 marker SNPs,
respectively, each for samples of 1,000 cases and 1,000
controls. For the lower causal-variant frequency (i.e., 0.05),
affected individuals tend to be heterozygous, rather than
homozygous, for the causal variant. As a result, it becomes
difﬁcult to disentangle the additive and dominance effects
of the causal variant, resulting in minimal gains by allow-
ing for deviations from a multiplicative model of disease
risks. However, for higher causal-variant frequencies (e.g.,
0.2 and 0.5), affected individuals homozygous for the
causal variant are more common, and there is, conse-
quently, a greater loss of information by ignoring domi-
nance, except in situations where the disease risks are ap-
proximately multiplicative—for example, a heterozygous
GRR of 2 and a homozygous GRR of 5.
Comparison with existing methods.—For each replicate of
data, I also perform a standard likelihood-ratio test of as-
sociation of disease with marker SNPs in the candidate
region, using the haplotype-based methodology devel-
oped by Zaykin et al.9 that does not allow for clustering
or dominance. Disease status is modeled in a logistic-re-
gression framework, parameterized in terms of the mul-
tiplicative risk of disease of each haplotype. To allow for
unknown phase, all possible pairs of haplotypes consistent
with the observed genotype data are considered, weighted
in the logistic-regression model by the corresponding
phase-assignment probability calculated from the maxi-
mum-likelihood estimates of the haplotype frequencies
already obtained via implementation of the EMalgorithm.
Rare haplotypes, occurring with estimated relative sample
frequency of !5%, are pooled to improve parsimony.
Figure 7 presents the power of the GENEBPMv2 algo-
rithm to detect association with the use of a 5% signiﬁ-
cance threshold, as a function of the disease model, for
candidate regions of 30 and 100 kb in length, typed at 5
and 20 marker SNPs, respectively, each for samples of
1,000 cases and 1,000 controls. The signiﬁcance threshold
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Figure 6. Mean L as a function of the disease model for samples of 1,000 cases and 1,000 controls for causative-allele frequencieslog10
of 0.05, 0.2, and 0.5 in a candidate region of 30 kb, typed at 5 SNPs (A), and for a causative-allele frequency of 0.2 in candidate
regions of 30 and 100 kb, typed at 5 and 20 SNPs, respectively (B). Also shown is the increase in the mean L by allowing forlog10
deviations from a multiplicative model of disease risks for samples of 1,000 cases and 1,000 controls for causative-allele frequencies
of 0.05, 0.2, and 0.5 in a candidate region of 30 kb, typed at 5 SNPs (C), and for a causative-allele frequency of 0.2 in candidate
regions of 30 and 100 kb, typed at 5 and 20 SNPs, respectively (D).
was determined from the null distributions of L for sam-
ples of 1,000 cases and 1,000 controls and was 0.639 and
0.678 for candidate regions of 30 and 100 kb, respectively.
As expected, power increases with the frequency of the
causative variant and with the strength of association be-
tween the disease and the functional polymorphism.
There is also greater power to detect association with 20
SNPs in a candidate region of 100 kb, compared with 5
SNPs in 30 kb, despite the increase in haplotype diversity,
the increased uncertainty in the phase-assignment pro-
cess, and the effects of recombination on the haplotype-
similarity metric.
Figure 7 also presents the gain in power of the
GENEBPMv2 algorithm over the standard likelihood-ratio
test of association of disease with marker SNPs in the can-
didate region, again evaluated using a 5% signiﬁcance
threshold. The GENEBPMv2 algorithm is generally as
powerful, with noticeable increases in power for causative
variants of frequency 0.2. The difference in power is most
noteworthy for candidate regions of 100 kb. With in-
creased marker-SNP haplotype diversity, it is most likely
that the causative variant is carried by several closely re-
lated rare haplotypes that can be identiﬁed through clus-
tering in the Bayesian partition model but that will be lost
through pooling by frequency.
Discussion
In the context of association with a binary trait, “domi-
nance” refers to any deviation from amultiplicativemodel
of disease risks. Allowing for dominance in haplotype-
based studies requires one parameter in the logistic-re-
gression model for each observed diplotype (i.e., pair of
haplotypes). Methods developed under this diplotype
model will lack power to detect association in a standard
frequentist-analysis framework, unless the deviation from
multiplicative disease risks is extreme. Lin et al.40 describe
a general-likelihood approach to test for association of a
single target haplotype with disease, allowing for domi-
nance. Their codominant model, which allows for devi-
ations from multiplicative risks of the target haplotype, is
less powerful than a multiplicative model for detecting
association of three SNPs in the XRCC1 gene with breast
cancer. Furthermore, they cannot simultaneously consider
the joint effects of all haplotypes in the gene without cor-
recting for multiple testing of each target one by one,
which is clearly suboptimal.
To overcome the problem of lack of parsimony, I use a
Bayesian partition model to cluster SNP haplotypes ac-
cording to their similarity, which is used as a proxy for
recent shared ancestry. Each haplotype allocated to the
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Figure 7. Power of the GENEBPMv2 algorithm to detect association, at a 5% signiﬁcance threshold, as a function of the disease
model for samples of 1,000 cases and 1,000 controls for causative-allele frequencies of 0.05, 0.2, and 0.5 in a candidate region of 30
kb, typed at 5 SNPs (A), and for a causative-allele frequency of 0.2 in candidate regions of 30 and 100 kb, typed at 5 and 20 SNPs,
respectively (B). Also shown is the increase in power to detect association, at a 5% signiﬁcance threshold, for the GENEBPMv2 algorithm
over a standard haplotype-based likelihood-ratio test for samples of 1,000 cases and 1,000 controls for causative-allele frequencies of
0.05, 0.2, and 0.5 in a candidate region of 30 kb, typed at 5 SNPs (C), and for a causative-allele frequency of 0.2 in candidate regions
of 30 and 100 kb, typed at 5 and 20 SNPs, respectively (D).
same clade is assigned the same probability of carrying a
causal variant at the functional polymorphism(s). By as-
suming that each causal variant has the same genetic effect
on disease, the logistic-regression model can be parame-
terized in terms of an additive component (the multipli-
cative contribution to risk) and a dominance component
(any nonmultiplicative contribution to risk). A similar ap-
proach has been used by Waldron et al.,21 in the context
of ﬁnemapping, by clustering phased SNP haplotypes into
just two clades, high- and low-risk, according to the Bayes-
ian partition model. In this way, inclusion of dominance
effects of causal variants at the functional polymor-
phism(s) requires only a single additional parameter over
a model of multiplicative disease risks. One of the main
advantages of this framework is ﬂexibility, since the lo-
gistic-regression model could easily be extended to incor-
porate interaction with nongenetic risk factors and epis-
tasis between functional polymorphisms in two candidate
regions, without introducing the large numbers of addi-
tional parameters that would be required in existing hap-
lotype-based methods.
I have developed a Bayesian reversible-jump MCMC al-
gorithm, GENEBPMv2, to sample from the posterior dis-
tribution of haplotype clusters and the corresponding
probabilities that they carry a causal variant at the func-
tional polymorphism(s), in addition to the additive and
dominance effects of the causal variant and any additional
covariate-regression parameters, given observed pheno-
type and genotype data. I allow for unphased genotype
data by considering all possible haplotype conﬁgurations,
weighted in the logistic-regression model by the corre-
sponding phase-assignment probabilities. These probabil-
ities are estimated by maximum likelihood via imple-
mentation of an EM algorithm, although other, more so-
phisticated haplotype-reconstruction techniques, such as
PHASE,12,13 could also be used. Output from the MCMC
algorithm can be used to estimate the Bayes factor in favor
of association, together with the posterior distribution of
additive and dominance effects of the underlying causal
variants. The current implementation of the algorithm
allows for up to 100 SNPs, or 2,000 distinct haplotypes,
consistent with the observed genotype data. Typically,
analysis of 20 SNPs, typed in 1,000 cases and 1,000 con-
trols across a 100-kb candidate region, requires !15 min
of computation time with a dedicated Pentium IV work
station.
The results of this simulation study suggest that there
is minimal cost associated with modeling the dominance
effects of causative variants at the functional polymor-
phism(s) within the Bayesian MCMC framework pre-
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sented here. In fact, there is an increase in the Bayes factor
in candidate regions of up to 100 kb when the causative
variants are common. Furthermore, I demonstrate in-
creased power of the GENEBPMv2 algorithm over a stan-
dard likelihood-ratio test of association of disease with
marker SNPs in the candidate region, using the haplotype-
based methodology developed by Zaykin et al.9 that does
not allow for clustering or dominance. These results
clearly demonstrate that, with an appropriate analysis,
such as GENEBPMv2, dominance effects can and should
be included in haplotype-based association studies to in-
crease power without substantial penalty for reduced
parsimony.
Analysis ofmarker-SNP haplotypes is appropriatewithin
candidate genes or small candidate regions subject to lim-
ited ancestral recombination. It is possible that even these
small regions will be spanned by a number of blocks of
SNPs in strong LD, interrupted by hotspots of recombi-
nation. Nevertheless, the results of this simulation study
suggest that the GENEBPMv2 algorithm performs well in
candidate regions of up to 100 kb, despite the fact that a
block model of LD was not used to generate the data. In
fact, the GENEBPMv2 algorithm performed best in can-
didate regions with increased haplotype diversity, partic-
ularly in comparison with existing haplotype-basedmeth-
ods that do not allow for dominance or clustering. Further
investigation is required to assess the detrimental effects
of recombination in genetic regions of 1100 kb. Of course,
haplotype-based analysis across several megabases or a
complete chromosome in a genome scan would be in-
appropriate because of the effects of recombination on the
clustering process and the expected inaccuracies in phase
assignment. Exceptions to this rule might include (i) tag-
ging SNPs selected within LD blocks, with each block an-
alyzed independently, and (ii) aggressively selected tag-
ging SNPs, which are often chosen to be tested in speciﬁc
combinations, as haplotypes, in the subsequent associa-
tion study.41,42 Furthermore, haplotype-based analyses
may provide additional information with high-density ge-
notyping in a follow-up study of associated regions from
an initial genome scan. The pattern of haplotype cluster-
ingmay help to reﬁne the likely location of the underlying
functional polymorphism(s) and may identify cases with
high probability of carrying causal variants to be se-
quenced for novel mutations.
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Appendix A
Glossary of Notation
yi Phenotype of individual i, where 0 indicates unaffected status and 1 indicates affected status
Gin Genotype of individual i at marker SNP n
xil Response of individual i for the lth covariate
Hj The jth most frequent marker-SNP haplotype consistent with genotype data
hj Estimated relative frequency of haplotype Hj
bA Additive effect of causal variants at the functional polymorphism(s)
bD Dominance effect of causal variant at the functional polymorphism(s)
Zi Genotype of individual i at the functional polymorphism(s)
K Number of clusters of marker-SNP haplotypes
Ck Marker-SNP haplotype center of cluster k
fk Probability that the haplotype in the kth cluster carries causal variant at the functional polymorphism(s) in
partition C
T (j)C Cluster assignment of haplotype in partitionH Cj
gl Logistic-regression coefﬁcient for the lth covariate
m Baseline log-odds of disease
v Model parameters {b ,b ,m,g,K,C,f}A D
D Observed data and estimated haplotype frequencies {y,G,x,h}
M Model of association between disease and polymorphisms in the candidate gene, where indicates themodelM0
with no association and indicates the model with associationM1
L Bayes factor in favor of disease association with polymorphisms in the candidate gene
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Appendix B
Details of the MCMC Algorithm
I have developed a reversible-jump Metropolis-Hastings MCMC algorithm to approximate the posterior-density func-
tion, , for model (eq. [4]), where and, for observed data, . For eachf (vFD,M) M v p {b ,b ,m,g,K,C,f} Dp {y,G,x,h}A D
iteration of the algorithm, a new set of parameter values, , is proposed according to predetermined weights, w, chosen′v
to optimize mixing and convergence (table A1). The proposed parameter values are substituted for the current set,
provided that
′( )f v FD,M
D 1 e ,( )f vFD,M
where e is a standard uniform random variable and D denotes the Hastings ratio of proposal probabilities,
′( )t v r v
D p .′( )t v r v
Otherwise, the current set of parameter values is retained. The possible changes to the parameter set are summarized
below, where e is a standard uniform random variable.
Table A1. Summary of Possible Changes to the Current Parameter Set in the Reversible-
Jump MCMC Algorithm
Change (j) Proposal Parameters
Relative Weights w (K)j
K p 1 K p 2 2 ! K ! n K p n
1 Cluster birth K, ,C f 0 .25 .25 0
2 Cluster death K, ,C f 0 0 .25 .25
3 Cluster-center swap C 0 .10 .10 0
4 Cluster center C 0 .10 .10 0
5 Causal-variant probability f 0 .10 .10 .10
6 Baseline log-odds of disease m .05 .05 .05 .05
7 Causal-variant additive effect bA 0 .05 .05 .05
8 Causal-variant dominance effect bD 0 .05 .05 .05
9 Covariate-regression coefﬁcient g .05 .05 .05 .05
Total weight W (K) .10 .75 1.00 .55
NOTE.—Relative weights for changes under the null model, , are given by . Relative weights for changesM K p 10
under the alternative model, , are given by .M K 1 11
Change 1: Propose a Cluster Birth
The proposed number of clusters is given by . Select a position, , at random for the new cluster in the∗K p K 1 k
list of ordered cluster centers. Select at random from a haplotype, , that is not already a cluster center, so thatH Hj
. Generate a new probability that haplotypes in the new cluster carry the causal variant at the functional′C p H∗k j
polymorphism(s), , from a uniform distribution. Then,′f ∗k
′ ′ ∗C p C and f p f if k ! kk k k k
and
′ ′ ∗C p C and f p f if k 1 k .k1 k k1 k
To ensure reversibility, .′ ′D p w (K )W (K) /w (K)W (K )2 1
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Change 2: Propose a Cluster Death
The proposed number of clusters is given by . Select a cluster, , at random for death. The proposed cluster∗K p K 1 k
centers and probabilities of carrying the causal variant at the functional polymorphism(s) are then given by
′ ′ ∗C p C and f p f if k ! kk k k k
and
′ ′ ∗C p C and f p f if k 1 k .k k1 k k1
To ensure reversibility, .′ ′D p w (K )W (K) /w (K)W (K )1 2
Change 3: Propose a Cluster-Center Swap
The following proposal procedure is performed K times. Select a pair of clusters, and , at random. The proposedk k1 2
cluster-center swap is given by
′ ′C p C and f p fk1 k2 k1 k2
and
′ ′C p C and f p f .k2 k1 k2 k1
.D p 1
Change 4: Propose a Cluster-Center Change
The following proposal procedure is performed K times. Select a cluster, k, at random. Select at random from aH
haplotype, , that is not already a cluster center, so that . .′H C p H D p 1j k j
Change 5: Propose a New Cluster Causal-Variant Probability
The following proposal procedure is performed K times. Select a cluster, k, at random. The proposed probability that
haplotypes in cluster k carry the causal variant at the functional polymorphism(s) is given by .′f p f  (e 0.5) /2k k
but, to ensure reversibility,D p 1
′ ′f if f ! 0′ k kf p .k ′ ′{ }2f if f 1 1k k
Change 6: Propose a New Baseline Log-Odds of Disease
The proposed parameter is given by , where nM denotes the maximum change in the parameter
′m p m n (e 0.5)M
value. .D p 1
Change 7: Propose a New Additive Effect of the Causal Variant
The proposed parameter is given by , where denotes the maximum change in the parameter′b p b  n (e 0.5) nA A A A
value. .D p 1
Change 8: Propose a New Dominance Effect of the Causal Variant
The proposed parameter is given by , where nD denotes the maximum change in the parameter
′b p b  n (e 0.5)D D D
value. .D p 1
Change 9: Propose a New Covariate-Regression Coefﬁcient
The following proposal procedure is performed L times. Select a covariate, l, at random. The proposed regression
coefﬁcient for the selected covariate is given by , where denotes the maximum change in the′g p g  n (e 0.5) nl l C C
parameter value. .D p 1
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